Cota, a data and technology platform for value-based precision medicine, released a lung cancer study conducted jointly with Novartis that compares real-world practice patterns of genetic testing of EGFR/ALK mutations versus published guidelines.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.Â
